- Home
- ABEO vs PINE Comparison
ABEO vs PINE Comparison
Compare ABEO & PINE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABEO
- PINE
- Stock Information
- Founded
- ABEO N/A
- PINE 2019
- Country
- ABEO United States
- PINE United States
- Employees
- ABEO N/A
- PINE N/A
- Industry
- ABEO Biotechnology: Pharmaceutical Preparations
- PINE Real Estate Investment Trusts
- Sector
- ABEO Health Care
- PINE Real Estate
- Exchange
- ABEO Nasdaq
- PINE Nasdaq
- Market Cap
- ABEO 277.6M
- PINE 239.5M
- IPO Year
- ABEO 1980
- PINE 2019
- Fundamental
- Price
- ABEO $6.41
- PINE $17.93
- Analyst Decision
- ABEO Strong Buy
- PINE Strong Buy
- Analyst Count
- ABEO 3
- PINE 7
- Target Price
- ABEO $18.00
- PINE $19.04
- AVG Volume (30 Days)
- ABEO 290.2K
- PINE 117.3K
- Earning Date
- ABEO 11-11-2024
- PINE 10-17-2024
- Dividend Yield
- ABEO N/A
- PINE 6.26%
- EPS Growth
- ABEO N/A
- PINE N/A
- EPS
- ABEO N/A
- PINE N/A
- Revenue
- ABEO N/A
- PINE $48,096,000.00
- Revenue This Year
- ABEO N/A
- PINE N/A
- Revenue Next Year
- ABEO $7,097.06
- PINE $2.84
- P/E Ratio
- ABEO N/A
- PINE N/A
- Revenue Growth
- ABEO 147.52
- PINE 5.44
- 52 Week Low
- ABEO $3.05
- PINE $14.25
- 52 Week High
- ABEO $9.01
- PINE $19.42
- Technical
- Relative Strength Index (RSI)
- ABEO 61.15
- PINE 51.12
- Support Level
- ABEO $6.39
- PINE $17.12
- Resistance Level
- ABEO $6.74
- PINE $17.63
- Average True Range (ATR)
- ABEO 0.31
- PINE 0.31
- MACD
- ABEO 0.02
- PINE -0.06
- Stochastic Oscillator
- ABEO 68.57
- PINE 61.60
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.
About PINE Alpine Income Property Trust Inc.
Alpine Income Property Trust Inc is a real estate company. It owns and operates a portfolio of single-tenant commercial properties. The company's portfolio is comprised of single-tenant retail and office properties located in or in close proximity to MSAs, growth markets and other markets in the United States. Their portfolio consists of One thirty eight net leased properties located in Hundred and four markets in thirty five states. The majority of the firm's revenue includes rental revenue derived from the ownership and leasing of property.